FTC issues more warnings to drug companies for ‘junk’ patent listings; Eli Lilly raises earnings guidance as Zepbound sales beat expectations

Taking stock of the drug industry, from the lab to the medicine chest

April 30, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | FTC issues warnings on 'junk' patent listings for Ozempic and other drugs "By filing bogus patent listings, pharma companies block competition and inflate the cost of prescription drugs," said FTC Chair Lina Khan. By Ed Silverman STAT+ | Eli Lilly raises earnings guidance as it ramps up Mounjaro, Zepbound manufacturing Zepbound, which was approved last November, brought in $517 million in sales in the first quarter of this year, more than analysts expected. By Elaine Chen STAT+ | 'Skinny labels' on generic medicines saved Medicare $15 billion over a recent six-year period Skinny labels allow a generic company to avoid lawsuits in which a brand-name manufacturer could claim patent infringement. By Ed Silverman Adobe Opinion: Protect the health of pregnant people and their children by including them in research New NASEM report: pregnant people should be part of research conducted for approving any medical product that such people would likely use. By Alexander M. Capron and Anna Mastroianni

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser